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Inflammatory bowel disease (IBD) is chronic, heterogeneous diseases characterised 
by excess inflammation in the gastrointestinal system and a dysfunctional mucosal 
immune response. Tumour necrosis factor (TNF) is a pleiotropic, pro-inflammatory 
cytokine upregulated in the serum and mucosa of IBD patients, compared to healthy 
controls (HCs). Anti-TNF treatment neutralises TNF, preventing the induction of 
downstream signalling pathways in immune cells. Cell death, pro-inflammatory and 
pro-survival responses can be mediated by TNF-induced ERK, p38 and NFĸBp65 
proteins. The functions of these proteins are diverse and context dependent. Up to 
40% of IBD patients do not initially respond to anti-TNF. It was hypothesised that the 
heterogeneity of TNF signalling in individuals may determine the anti-TNF response. 
TNF signalling pathways in peripheral blood mononuclear cells (PBMCs), derived from 
IBD patients and HCs, were activated using TNF stimulation or pan-stimulation by 
PMA/ionomycin. A phosphoflow cytometry protocol was optimised to allow 
visualisation of phosphorylated (activated) proteins in immune cells, in response to 
stimulation. Changes in phosphorylation were measured by normalised fold changes 
in mean fluorescence intensity (MFI). There was no difference in phosphorylated (P) 
p38, P-ERK or P-NFĸBp65 expression in CD3+ CD4+ T cells or CD14+ CD64+ 
monocytes between healthy (n=8) and IBD (n=5) groups (all p>0.05, Mann-Whitney U 
test). However, one IBD patient had comparatively higher P-p38 expression in CD3+ 
CD4+ T cells (MFI fold change = 3.8) and lower expression of P-NFĸBp65 in CD3+ 
CD4+ T cells (MFI fold change = 2), in response to PMA/ionomycin stimulation. A 
second patient had comparatively higher NFĸBp65 phosphorylation (MFI fold change 
= 6.21) in response to PMA/ionomycin stimulation, compared to IBD and HC 
individuals. Interestingly, the first patient was an anti-TNF non-responder. This study 
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provides preliminary data showing the extent of individual heterogeneity in immune 
response. This study supports the individual analysis of IBD patients to inform the 
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1. Introduction  
Inflammatory bowel disease (IBD) is an umbrella term used to group heterogeneous 
diseases pathologically characterised by excess inflammation in the gastrointestinal 
tract (1). IBD is a relapsing, chronic condition, with periods of remission and active 
disease. During active periods of disease patients may experience fever, bloody 
diarrhoea, abdominal pain, intestinal mucosal lesions, fatigue, and weight loss. IBD 
manifests primarily as two clinically distinct diseases, Crohn’s disease (CD) and 
ulcerative colitis (UC); although, these phenotypes likely represent two ends of a 
spectrum. Inflammation observed in CD can involve the whole gastrointestinal tract 
and present in a discontinuous manner; however, UC shows continuous inflammation 
restricted to the colon and rectum. Inflammation in UC is superficial, primarily affecting 
the mucosa and submucosa; inflammation in CD is transmural (1).  
IBD is multifactorial and highly complex. Four pathogenic factors are involved in the 
development of disease; genetics, the environment, the immune response and the 
microbiome (1). Multiple genetic susceptibility loci have been implicated in IBD 
pathogenesis  (2); however, not all genetically susceptible individuals will develop 
disease, indicating a role for environmental triggers (1). Microbiome dysbiosis and the 
deregulated immune response are also contributing factors to IBD onset (1, 3). 
Whether these factors are a cause or consequence of one another is not well 
understood, meaning the exact aetiology of disease is unknown. Given the implication 
of many genetic susceptibilities in IBD, the pathological mechanism is likely to vary 
between individuals, contrasting with conventional disease classification dogma. 
As of 2019, the reported overall global incidence of IBD is stabilising (4, 5). Whilst 
some countries such as Canada and America report a decline in incidence, it is 
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increasing in newly industrialised areas of Asia, Latin America and Africa, for reasons 
which are unclear (4, 5). New Zealand has one of the highest incidences of IBD world-
wide, with 30+ per 100,000 person-years, according to population-based studies 
collated over the past 9 years (4). Specifically, southern areas of New Zealand have 
shown significant increases in incidence (6, 7). In 2004, the age-standardised 
incidence of CD in the Canterbury region was 16.3 per 100,000 person-years, 
compared to 26.4 per 100,000 person-years ten years later, in 2014 (7).  
1.1  Characterisation of IBD pathology as a dysfunctional mucosal 
immune response  
The intestinal mucosal immune system comprises several ‘barriers’ which cooperate 
to maintain homeostasis of the intestinal lumenal environment (3, 8). The intestinal 
lumen allows passage of dietary antigens and accommodates commensal organisms 
which comprise our intestinal microbiome. The microbiome is symbiotic, benefiting 
human health (3). The mucosal immune system must therefore maintain the 
microbiome, whilst preserving the ability to clear pathogens and repair damaged 
tissue. To do this, the mucosal immune system delineates between when to elicit an 
inflammatory and non-inflammatory response (9). For these reasons, the 
gastrointestinal environment is not typically an inflammatory environment but rather a 
tolerogenic environment. The intestinal epithelial barrier (IEB) and the intestinal 
immune cells populating the lamina propria and paracellular spaces of the IEB are two 
important ‘barriers’ for maintaining intestinal mucosal homeostasis (8).  
A network of intestinal epithelial cells constitutes the IEB. The IEB tightly regulates the 
interactions between lumenal antigens and mucosal immune cell populations through 
the compartmentalisation of the lymphocyte rich lamina propria (LP) and the intestinal 
lumenal contents (Figure 1.1) (8). Cells of the IEB are joined by molecular protein 
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structures called tight junctions. Tight junctions stringently regulate paracellular flow 
across the intestinal epithelium. Therefore, the IEB aids the prevention of 
microorganism translocation into deeper tissue and therefore potential infection (8). 
Epithelial cells of the IEB also have anti-microbial properties to reduce the colonisation 
of pathogenic microbes, such as the production of antimicrobial peptides and 
production of mucus to prevent colonisation of pathogens (10).  
Tolerogenic immune responses enable commensal species to live with the human 
host symbiotically, whereas a protective inflammatory response is elicited against an 
invading pathogen (9). Tolerance is largely mediated by functionally suppressive 
immune cells such as forkhead box p3 (FOXP3)+ CD4+ regulatory T cells (Tregs). 
FOXP3 is a transcriptional regulator of Tregs, meaning it can control the anti-
inflammatory function of regulatory T cells through transcription of inhibitory proteins 
(11). Tregs can limit inflammation through multiple suppressive functions, including 
the production of anti-inflammatory cytokine, such as interleukin-(IL)10. IL-10 receptor 
mutations and reduced IL-10 production has been implicated in some IBD 
pathogeneses, resulting in an inability of inflammatory T cells to respond to immune 
suppression via IL-10 (12).  Anti-inflammatory cytokines can act on other immune cells 
to reduce an inflammatory response and Tregs can be ‘induced’ in response to 
commensal antigen (see section 1.2). 
In IBD, intestinal homeostasis mediated by the mucosal immune system is presumed 
to be compromised. The IEB in IBD patients appears ‘leaky’, resulting in the infiltration 
of lumenal antigen into the lamina propria (Figure 1.1) (1). Intestinal immune cells of 
IBD patients induce inflammatory responses without control and the gut transforms 
from a tolerogenic to an inflammatory environment. It is unclear whether the 
pathological inflammation is in response to the infiltration of lumenal antigen, 
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supporting the hypothesis that the leaky IEB precedes inflammation; or if the IEB 
becomes compromised due to inflammation-mediated tissue damage and the 
infiltration of antigen perpetuates the chronic nature of inflammation and therefore the 
disease.  
1.2   Overview of the immune response in IBD 
Given the plasticity and heterogeneity of the immune response, understanding its 
exact role in IBD is complicated and likely to vary between individuals. Plasticity and 
heterogeneity refer to the fact that immune cell populations can exist in a spectrum 
between functional, transient phenotypes. Such phenotypes are influenced by cellular 
interactions, the extracellular environment, and chemical communicators, such as 
cytokines (3). Briefly, antigen-presenting cells (APCs), such as monocytes, encounter 
lumenal antigen via pattern recognition receptors. Upon APC presentation to T cells, 
polarising cytokines are produced by APCs to influence the functional phenotype of T 
cells. APCs can sense ‘harmful’ from ‘non-harmful’ antigen, where commensal 
microbiota would be an example of the latter and this may result in the induction of 
Tregs, for example (3, 8). Therefore, this interaction is important for determining what 
type of immune response is elicited; inflammatory or tolerogenic. Whilst IBD has been 
primarily categorized as a T-cell mediated disease, there is a significant role for APCs 




Figure 1.1. Schematic diagram of a healthy intestinal environment compared to IBD pathology. On the left (non-
IBD), the intestinal epithelial barrier (IEB) is intact and compartmentalises the intestinal lumen and lamina propria. The 
intestinal lumen allows passing of dietary antigen and houses intestinal bacteria. The lamina propria houses immune cells 
such as T cells and monocytes. On the right (IBD), the IEB becomes leaky as indicated by gaps between epithelial cells. 
Intestinal lumenal constituents infiltrate the lamina propria. T cells and monocytes are activated (red T cells and red 
monocytes) and inflammation occurs, as indicated by the red IEB. Information adapted from (1, 3, 8). 
 
Figure 1.2  MAPKs and NFkB are activated downstream of TNF-receptor binding.Figure 1.3. Schematic diagram of 
non-IBD intestinal environment compared to IBD pathology. On the left (non-IBD), the intestinal epithelial barrier (IEB) is 
intact and compartmentalises the intestinal lumen and lamina propria. The intestinal lumen allows passing of dietary 




Two major cell types implicated in IBD pathogenesis, that are potent producers of pro-
inflammatory cytokine such as tumour necrosis factor (TNF), are monocytes and T 
cells. Monocytes are myeloid-lineage derived cells circulating in blood. Monocytes 
differentiate into tissue-resident macrophages. Monocytes and macrophages 
modulate intestinal homeostasis and the immune response through regulating T cell 
response. CD3+ CD4+ and CD3+ CD8+ T cells respond to antigen presentation and 
can activate or suppress an inflammatory response. 
Inflammatory cytokines such as TNF and IL-23 derived from monocytes and 
macrophages are upregulated in the mucosa and serum of IBD patients compared to 
HCs (13-15). Monocytes are thought to be the only source of intestinal macrophages. 
In CD patients, classical CD14+ CD16- monocytes were decreased as a proportion of 
PBMCs (16), but this is likely because they differentiate into pro-inflammatory 
macrophages in the gut tissue (17). Non-classical CD14+ CD16high monocytes are also 
effective producers of TNF; although their proportion was unaltered in CD patients 
compared to non-IBD patients (17), this does not exclude the possibility that TNF 
production may be increased, depending on the activity of cell signalling pathways. 
Conventionally, T cell phenotype could be determined by the production of specific 
cytokines, mediated by a specific transcriptional programme. However, as previously 
established in literature and in the Kemp laboratory (18, 19), subsets of T cells in IBD 
are found to be poly-cytokine producing, negating the use of binding phenotypes. 
Effector T cells producing interferon-gamma (IFN), TNF, IL-5, IL-17, IL-22, IL-21, IL-
23 pro-inflammatory cytokines have been found to be upregulated in patients with 




1.3 Tumour necrosis factor  
TNF is one of the major inflammatory mediators implicated in IBD pathogenesis and 
is produced by both APCs and T cells (20, 21). TNF is a heterotrimeric transmembrane 
protein bound to cell membranes (mTNF), which upon proteolytic cleavage by TNF-
alpha converting enzymes, becomes soluble (sTNF) (21).TNF is one of the 19 
pleiotropic ligands in the tumour necrosis factor superfamily; structurally similar 
proteins involved in the activation of diverse signalling pathways resulting in 
inflammation, proliferation, cell survival, differentiation, and cell death (20). These 
pathways are activated as the result of cellular phenotype, context, and the 
extracellular environment.  
TNF expression in the gastrointestinal mucosa and serum of IBD patients is 
upregulated, compared to non-IBD controls (22, 23). TNF can directly induce pro-
inflammatory signalling pathways and augment the expression of other pro-
inflammatory interleukins implicated in IBD pathogenesis (20, 22). In homeostasis, 
TNF maintains the balance of cell survival and cell death of intestinal cells for 
homeostatic cell turnover of the gut epithelium (22). In the context of IBD, TNF 
contributes to IEB degeneration, potentially through an imbalance in TNF-mediated 
apoptotic pathways over pro-survival pathways in intestinal epithelial cells. However, 
He and authors (2012) (24) show evidence of TNF-induced NFĸBp65-mediated tight 
junction protein disorganisation in a Caco cell line, which may be represented in IBD 
pathology. 
TNF signalling  
Pleiotropy of TNF is mediated by complex signalling pathways activated downstream 




TNFR1 is constitutively expressed on many cell types, including immune cells, 
epithelial cells, and neurons. TNFR2 expression is highly regulated, and 
predominantly restricted to endothelial and hematopoietic cells (25). TNFR1 mediated 
signalling can be induced by either sTNF or tmTNF, whereas TNFR2 signalling is 
primarily mediated via tmTNF binding. Signalling cascades downstream of TNF 
receptors may appear paradoxical in function, influencing both cell death and cell 
survival responses under different cellular contexts. Ligand interaction with either 
TNFR1 and TNFR2 can mediate pro-inflammatory responses, including those 
mediated by nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB)-
p65 and mitogen-activating protein kinases (MAPKs) (26, 27)  (Figure 1.2). TNF-
mediated pro-survival cell responses enable inflammatory T cells to persist. TNFR1 is 
distinct from TNFR2 through its association with a death domain adaptor, TNFR1-
associated death domain protein (TRADD), classically linked to the initiation of cell 
death (see figure 1.2) (25). Underpinning the pleiotropic function of TNF, therefore, is 
cell phenotype, receptor interactions, and cellular context.  
NFĸBp65 
Activation of the pro-inflammatory transcription factor NFκB in response to TNF-
receptor binding is well characterised. TNFR1 is known to be a more potent activator 
of NFκB than TNFR2 (28). The NFκB family consists of five structurally related 
transcription factors that can regulate inflammation through the transcription of 
inflammatory cytokines and pro-survival responses. Indeed, many of the pro-
inflammatory cytokines implicated in IBD pathogenesis are transcriptionally regulated 
by NFκB (1, 29). TNFR1-mediated NFĸBp65 signalling is initiated by a signalling 




associated factor (TRAF2), cellular inhibitor of apoptosis protein 1/2 (cIAP1/2), an E3 
ubiquitin ligase, and serine/threonine protein kinase 1 (RIPK1) (Figure 1.2) (25). 
RIPK1 ubiquitination by cIAP1/2 forms a scaffolding platform for the recruitment of the 
TAK1-TAB complex and linear ubiquitin assembly complex (LUBAC), which are 
subsequently ubiquitinated (25). These complexes, along with RIPK1, collectively 
ubiquitinate and phosphorylate protein constituents of the NFκB inhibitory complex. 
Following this, IκB, the inhibitor of NFκB subunits, is phosphorylated and degraded via 
proteasomes, allowing the nuclear translocation of p65 and p50. TNFR2 mediated 
NFĸBp65 signalling is initiated by the same signalling complex proteins excluding 
TRADD and RIPK1 and is regulated by the LUBAC and the TAK1-TAB complex in a 
similar way to TNFR1 signalling (21). 
MAP Kinases ERK and p38 
Both TNF receptors activate MAPKs: extracellular signal-regulated kinases (ERK), c-
Jun NH2-terminal kinases, and p38 MAPK (25). MAPK activation occurs in response 
to multiple stimuli including stress/inflammation, growth factors, hormones, and IL-
receptor binding (27). Activation of MAPKs generally involve a phosphorylation 
cascade; MAPK kinase kinases (MAP3K) activation followed by MAPK kinase 
(MAP2K) activation, and subsequently ERK or p38 (MAPK) activation. This hierarchy 
of MAPK regulation allows for integration and cross talk between multiple pathways 
activated by different stimuli; therefore, MAPKs can have plastic and diverse roles 
across cell types and depending on cell context (27).  
The main pathway described for TNF-mediated activation of ERK1/2 isoforms occurs 
via RIPK1 mediated ubiquitination of TAK1 (Figure 1.2) (27). TAK1 alters the inhibitor 




phosphorylates proteins in the complex inhibiting tumour progression locus 2 (TPL2), 
which results in its release and Iĸĸβ-mediated phosphorylation (30). TPL2 
phosphorylates MAP2Ks, MKK1 and 2, which cooperatively phosphorylate ERK. It is 
not known whether TAK1 from the TAK/TAB complex can directly phosphorylate 
MAP2Ks, MKK1 and MKK2, to induce ERK activation (31). Phosphorylation of ERK 
results in the activation and nuclear translocation of transcription factors such as 
activating protein 1 (AP-1) which can promote proliferation, differentiation and cell 
migration (32). TNF-mediated activation of p38α is linked to many upstream MAP3Ks, 
such as TAK1 and apoptosis signal regulated kinase 1 (ASK1), which result in different 
cell fates (Figure 1.2) (27). At cell rest, ASK1 is in an inactivated state when bound by 
thioredoxin. In the presence of reactive oxygen species (ROS), thioredoxin dissociates 
from ASK1. ASK1 then associates with TRAFs resulting in confirmational change of 
ASK1 (27). ASK1 then phosphorylates MAP2Ks, MKK3 and MKK6, resulting in the 
cooperative phosphorylation of p38. In this context, p38 is activated to mediate a cell 
death response. However, other MAP3Ks such as TAK1 are involved in T cell survival 
and proliferation responses and pro-inflammatory cytokine production, despite also 
acting through phosphorylation of MKK3 and MKK4 (27). This accentuates the 
importance of upstream regulators in signalling cascades when only considering the 
activity of one protein as a representative of a signalling pathway; there can be multiple 





Figure 1.2 Tumour necrosis factor signalling pathways. TNF-TNFR1 binding recruits TNF 
receptor associated death domain (TRADD), TNF alpha associated factor (TRAF2), E3 ubiquitin 
ligase (cIAP1/2) and serine/threonine protein kinase (RIPK1), comprising the TNFR1 signalling 
complex. The same proteins constitute the TNFR2 signalling complex, excluding RIPK1. Both 
receptors mediate canonical NFkB activation (orange), primarily through association with 
ubiquitinated linear ubiquitin assembly complex (LUBAC) and the TAK-TAB complex, which trigger 
the phosphorylation of proteins constituting an inhibitory complex. Dissociation of the inhibitory 
complex results in the proteasomal degradation of NFĸB inhibitor, IĸB, allowing the phosphorylation-
mediated nuclear translocation of NFĸB subunit p65. Both receptors can also activate ERK and p38 
MAPK (blue) pathways. TAK1 indirectly activates ERK through interaction with the NFĸB-associated 
inhibitory complex, which results in Iĸĸβ release. Iĸĸβ phosphorylates inhibitory proteins of tumour 
progressive locus (TPL2) and phosphorylates TPL2. TPL2 phosphorylates MAPK kinases (MKK)1 
and 2 which in turn cooperatively phosphorylate ERK. TAK1 may also be able to directly activate 
MKK1 and MKK2. P38 phosphorylation can be induced by apoptosis signal-regulating kinase (ASK1). 
ASK1 is released from an inhibitory protein in the presence of reactive oxygen species (ROS). ASK1 
forms functional complexes with TRAFS from either TNFR1 or TNFR2 signalling complexes. 
ASK1/TRAF complexes can phosphorylate MKK3 and MKK6 which cooperatively phosphorylate p38, 
resulting in a cell death response. TAK1 can also induce p38 activity through direct phosphorylation 
of MKK3 and MKK6. Both ERK and TAK1-mediated p38 activation can result in NFĸB activation as 
well as other transcription factors involved in inflammation, proliferation and survival. Adapted from 




TNF signalling is diverse 
MAPK and NFĸBp65 are known to be upregulated in an active state in IBD patients 
compared to non-IBD controls (27, 33, 34). Evidence supports the role of these 
proteins in the production of pro-inflammatory cytokine in effector T cells, however, 
this is not to negate their signalling diversity and potential heterogeneity.  
NFkBp65 is a diverse transcription factor activated by a diverse range of stimuli, 
regulating gene transcription in an abundance of cell types including cardiomyocytes, 
smooth muscle cells and immune cells (35). For example, both ERK and p38 MAPK 
can activate transcriptional regulation by NFĸBp65 (Figure 1.2). Functions of NFĸBp65 
across cell types have involved apoptosis, anti-apoptosis, cell proliferation and 
differentiation. In the context of IBD, NFĸBp65 has been evidenced as a major 
transcriptional regulator for most of the pro-inflammatory cytokines implicated in IBD 
pathogenesis (36). CD patients were found to have upregulated protein expression 
and nuclear localisation of the p65 subunit in lamina propria macrophages (29). Whilst 
it should be acknowledged that mouse models of intestinal inflammation do not 
necessarily reflect the pathological mechanisms of IBD, inhibition of p65 with 
antisense oligonucleotides resolved intestinal inflammation in a chemically induced 
colitis mouse model (37). 
As mentioned, MAPK signalling is interconnected, allowing for the integration of 
signalling pathways in response to multiple stimuli (27). The dynamic signalling of 
MAPKs may explain their functional diversity and thus, varying therapeutic outcomes 
following their inhibition in inflammatory disease models. For illustration, p38 isoforms 
can regulate the ERK pathway through TPL2 stabilisation in dendritic cells upon 




IBD pathogenesis also, provided there is an infiltrate of bacterial antigen into the LP 
(38). 
Studies have shown conflicting evidence for the involvement of ERK in the Th17/Treg 
differentiation axis, which are two transient cell phenotypes implicated in IBD 
pathogenesis (39-41). As a proportion of T cells, Th17 T cells or IL-17 producing pro-
inflammatory T cells are upregulated in IBD patients compared to HCs (42, 43). Two 
studies found ERK activation to be important in the polarisation of T cells towards an 
IL-17 producing phenotype (40, 41). A study by Liu and authors (2013) (41) 
investigated the role of ERK in CD4+ T cells through inhibition via inhibitor molecule 
PD098059, which resulted in decreased IL-17 production of T cells incubated with 
Th17 classical polarizing cytokine. This inhibition also increased production of anti-
inflammatory cytokine IL-10 (41). The same authors corroborated this, showing that 
ERK-inhibited T cells caused inflammation in an adoptive transfer colitis model. 
However, ERK inhibition studied by Tan and colleagues (2010) (39), found 
upregulated IL-17 and TNF production of Th17 polarised murine T cells with ERK 
inhibition, and less IL-10 production. This was then found to exacerbate colitis in 
immunodeficient mice (39), conflicting results presented by Liu et al (44). 
Similar controversy is seen with the role of p38 in determining T cell function.  As 
noted, p38 can be involved in cell death as well as cell survival and proliferation. 
Further, there have been conflicting reports on the outcome of p38 inhibition in 
inflammatory disease models. Multiple studies evidence the importance of p38 for the 
activation and proliferation of Tregs, predominantly mediated by TNFR2-TNF 
signalling (34, 45-47). This has been indicated by a reduction in Tregs upon specific 




inflammatory cell subsets and cytokines, yet selective inhibition of p38 has shown to 
ameliorate inflammatory disease severity indexes in rodent models of chemically 
induced colitis (46, 48). This is likely due to a reduction of p38-mediated pro-
inflammatory cytokine in effector T cells, irrespective of p38’s role in Tregs. However, 
one study did challenge the significance of p38 inhibition in a chemically-induced colitis 
mouse model, with results showing no reduction in inflammation or therapeutic benefit 
following p38 inhibition (49). Additionally in this study, IBD patient biopsies showed 
reduced p38 activity in response to chemical inhibition, but no biological or clinical 
effect, minimizing the role of p38 inhibition as a therapeutic target in chronic 
inflammation (49).  
Evidently, these examples have alluded to the complexity and diversity of 
downstream-TNF signalling proteins. The present study focuses on only three 
pathways downstream of TNF so it is important to acknowledge the broader 
complexity: there are many regulators for transcription in a single response to TNF, 
multiple stimuli can be integrated at different levels of a signalling cascade, and there 
is significant crosstalk between pathways (20).  
1.4  Anti-TNF therapy 
Due to the role of TNF and its downstream effector proteins in inflammatory disease, 
it is the molecular target of anti-TNF therapy (50). Anti-TNFs are a group of 
recombinant antibodies which neutralise soluble or membrane bound TNF to prevent 
the induction of TNF-mediated inflammatory pathways (51). Anti-TNFs are commonly 
used in patients with inflammatory diseases such as psoriasis, rheumatoid arthritis 
(RA) and IBD. Two commonly used anti-TNFs are monoclonal antibodies, Infliximab 




murine variable regions, whereas the Humira antibody is essentially identical to human 
immunoglobulin G 1 (IgG1) (50).  
There are other mechanisms by which anti-TNFs work other than sequestering TNF 
molecules to prevent the induction of pro-inflammatory pathways (51). Anti-TNFs 
induce suppressive immune cell phenotypes, and reduce inflammatory immune cells 
by either the induction of apoptosis or by reducing pro-inflammatory cytokines (51). 
Either directly or indirectly through reduced inflammation, anti-TNFs also ameliorate 
IEB integrity (52). 
Whilst anti-TNF has been a revolutionary milestone compared to conventional 
treatments such as the use of corticosteroids and thiopurines, therapeutic response is 
disparate (51). Between 13-40% of IBD patients do not respond to anti-TNF and of the 
primary responders, up to 46% develop resistance (53). Mechanisms for both primary 
and secondary non-response are not well understood. Secondary non-response may 
be the result of anti-anti-TNF antibodies, but these are not detected in all secondary 
non-responders (52). The initial non-response is likely to vary between individuals and 
may be the sum of multiple factors but is yet to be robustly investigated in literature. 
1.5 Hypotheses and Aims 
I hypothesised that a potential contributor to, or explanation for, anti-TNF non-
response with respect to inflammation regulation, may be due to the intrinsic 
differences in TNF signalling pathways. This hypothesis is based on the conflicting 
reports on outcomes of selective inhibition of TNF signalling proteins and how these 




My overall aim was to study the activation of pathways downstream of TNF signalling, 
in immune cells from HC vs IBD patients, to determine the variability between 
individuals. A secondary aim was to correlate the phosphorylation of TNF-mediated 
signalling pathways with the individual patient’s response to anti-TNF therapy.  
To address this hypothesis, the following aims were developed: 
1. Develop and optimise a phosphoflow protocol to visualise the phosphorylation 
(activation) of TNF signalling pathways: p38, ERK and NFĸBp65  
2. Compare p38, ERK and NFĸBp65 signalling pathway responses of T cells and 
monocytes between IBD and HC groups, in response to in vitro stimulation with 
PMA/ionomycin and recombinant TNF 
3. Compare individual IBD patients p38, ERK and NFĸBp65 signalling in T cells 
and monocytes, in response to in vitro stimulation with PMA/ionomycin and 
recombinant TNF  




2. Methods  
2.1 Ethics approval 
Ethical approval for the use of IBD patient blood and healthy control (HC) blood in this 
study was obtained from the University of Otago Human Ethics (Health) Committee; 
approvals H18-088 and H17-117. A total of 8 HCs were used for comparison to the 
IBD group. The age of HCs ranged from 28 years to 65 years. Three HCs were male, 
and five HCs were female. 
Members of the research group recruited healthy controls from the University of Otago, 
and IBD patients from the Dunedin Hospital, New Zealand. Written, informed consent 




Table 2.1 Table of IBD patient characteristics  





Patient 1 45 Female Crohn’s: terminal 




Patient 2 51 Male Crohn’s; Terminal 
ileum 
Active Azathioprine Pentasa No 
Patient 3 36 Female Crohn’s  Active Alopurinol, Humira, 






      Patient 4 63 Male Non-stricturing 
Crohn’s; colon 





Patient 5 29 Female Non-stricturing 
Crohn’s; terminal 
ileum  
Undefined  Prednisone  Prednisone No 




2.2 Media and reagents  
RMPI culture media 
Roswell Park Memorial Institute (RMPI) 1640 medium (Gibco, Invitrogen, Auckland, 
New Zealand) was used to culture cells. RMPI 1640 medium was supplemented with 
10% foetal calf serum (FCS) (Gibco, New Zealand Origin); 0.1% 2-mercaptoethanol 
(Gibco, Thermo Fischer Scientific, Waltham, Massachusetts, USA); and 5 mL 10,000 
U/mL penicillin-streptomycin (Gibco, Thermo Fisher Scientific).  
PBS 
10 x phosphate buffered saline (PBS, pH 7.4) was made with 160 g sodium chloride 
(Scharlab, Barcelona, Spain), 5 g potassium chloride (Scharlab, Barcelona, Spain), 
22.7 g sodium phosphate (Merk, Darmstadt, Germany) and 4 g monopotassium 
phosphate (Merk, Darmstadt, Germany) dissolved in distilled water. 1X PBS was 
made from 10X PBS diluted with distilled water. PBS was filtered sterilized with 0.22 
µm pore-sized bottle top-filters (Corning, Glendale, Arizona, USA) and kept at 4 ˚C. 
FACS buffer 
One litre fluorescence activated cell sorting (FACS) buffer was made with 1x PBS, 5 
mL FCS (Gibco, New Zealand) and 0.1 g/L sodium azide (Avantor, Leicestershire, 
England). FACS buffer was filter sterilised with 0.22 µm pore-sized bottle top-filters 
(Corning, USA) and stored at 4˚C. 
Freezing media 
90% FCS (Gibco) was mixed with 10% dimethyl sulfoxide (Sigma Life Sciences, 




2.3 Blood sample processing  
Blood sample collection  
Blood samples were collected in 10 mL vacutainer blood collection tubes with heparin 
(Becton Dickinson, Franklin Lakes, New Jersey, USA). Samples were transported on 
ice, in a biohazard bin from Dunedin Hospital to a PC2 laboratory in the Microbiology 
and Immunology building, University of Otago.  
Isolation of PBMCs 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples by a 
density gradient method. Blood was diluted 1:2 with 1x PBS and transferred to a 
SepMate PBMC isolation tube (STEMCELL Technologies, Vancouver, Canada) 
containing 15 mL Ficoll-Paque density medium (GE Healthcare, Chicago, Illinois, 
USA). The sample was then centrifuged at 800 x g at 20 ˚C for 10 minutes. The top 
layer of the SepMate tube was decanted into a 50 mL Falcon tube (Corning, Glendale, 
Arizona). This was diluted with 1x PBS to a total volume of 50 mL. The sample was 
then centrifuged at 300 x g at 20 ˚C for 8 minutes. The supernatant was discarded, 
and the pellet was resuspended in 10 mL PBS. The sample was centrifuged at 300 x 
g at 20 ˚C for 8 minutes. The supernatant was discarded, and the pellet was 
resuspended in 1 mL RPMI 1640 culture medium. A cell count was performed. If 
PBMCs were being used immediately, cells were seeded into corresponding wells at 
1.5 x105 - 3x105 cells per well. PBMCs from samples were either used immediately or 
frozen in liquid nitrogen. 
PBMC freezing  
Samples were frozen and stored if they were not being used immediately for an 




at 582 x g at 4 ˚C for 4 minutes. The supernatant was discarded. The pellet was 
resuspended in 1 mL freezing media. This was then transferred to cryotubes 
(Greineier bio-one, Bioscience, Maybachstr, Germany) and stored in a -80 ˚C freezer 
for 24 hours before being transferred to a liquid nitrogen dewar. 
Frozen PBMC thawing  
Samples were retrieved from the liquid nitrogen and thawed out by pipetting 1 mL 
aliquots of warmed RPMI 1640 culture media into the cryotube and transferring to a 
15 mL Falcon tube (Corning, Glendale, Arizona, USA). The cell solution was washed 
twice in 1 mL RMPI 1640, then resuspended in 1 mL RMPI 1640.  
Cell counting  
A 10 µL aliquot of cell sample was diluted 1:2 with 10 µL of 0.4% trypan blue (Life 
Technologies, Carlsbad, California, USA). A 10 µL aliquot of this was then loaded in a 
Luna Disposable Cell Counting Slide (Logos Biosystems, South Korea) and analysed 
using the Luna II Automated Cell Counter set to the PBMC protocol (Logos 
Biosystems).  
2.4 Stimulation of samples 
PBMCs were stimulated to promote phosphorylation of intracellular proteins, prior to 
cytometric analysis. Stimulated samples were stimulated with either 50 ng/mL phorbol 
12-myristate 13-acetate (PMA) (Sigma-Aldrich, St Louis, Missouri, USA, cat#P1585) 
and 50 ng/mL ionomycin (Sigma-Aldrich, cat# 10634) or 100 ng/mL recombinant TNF-
alpha (R&D Systems, Inc. Minneapolis, Minnesota, USA, cat# 210-TA) and placed in 




2.5 Surface staining - flow cytometry  
Flow cytometry protocols were established by a previous member in the lab. Basic 
principles are described here, however, optimisation was part of my research as 
shown in Results, Figure 3.1 – Figure 3.9.   
Compensation  
Compensation beads were prepared using OneComp eBeads (Invitrogen, Carlsbad, 
California, USA). Beads were incubated with 1 uL of each antibody or left unstained 
for an unstained control. For compensation of live/dead viability stain, live and dead 
cells were combined and used instead of beads. This allowed the compensation of 
spectral overlap of fluorochromes in flow cytometry.  
Viability staining  
Live/Dead Near Infrared Fixable Amine Reactive Dye (Invitrogen) was used for viability 
staining. Viability dye was diluted 1:1000 with 1x PBS to create a master mix. Samples 
were washed once with 100 µL 1x PBS and stained with 100 µL Live/Dead master 
mix. Samples were then incubated on ice for 30 minutes in the dark. Following this, 
samples were washed twice with 100 µL FACS buffer.  
To use as a compensation control, a proportion of cells were exposed to absolute 
ethanol for 15 minutes, then washed twice with PBS. These dead cells were then 
combined with live cells and stained with Live/Dead viability dye as above.  
Antibody titrations 
All antibodies for surface staining and phosphoflow were titrated on fresh HC PBMCs 
prior to use in experiments (Results, Figure 3.10). Commercial antibodies were 




Extracellular staining  
Extracellular staining was completed using an established lab protocol. Samples were 
stained with titrated antibody in wells of a 96 well plate.  A master mix was created 
with the appropriate dilutions for each extracellular-staining antibody (Table 2.2) and 
FACS buffer. Calculations were made so that each sample was stained with 25-100 
µL surface master mix.  
2.6 Fixation 
Paraformaldehyde fixation  
Basic surface staining flow cytometry samples were fixed in 100 µL 1% 
paraformaldehyde (PFA) (Sigma-Aldrich) on ice for 30 minutes in the dark. Samples 
were washed twice with FACS buffer. If not completing intracellular staining, samples 
were then resuspended in 200 µL FACS buffer for LSR Fortessa (BD BioSciences, 
California, USA) analysis. 
BD cytofix fixation  
BD cytofix fixation buffer (BD Sciences, San Diego, California, USA) was used for 
phosphoflow. BD cytofix fixation buffer was preheated in a 37 ˚C water bath for 10 
minutes prior to use. All samples and controls were fixed in prewarmed 100 µL fixation 
buffer. Samples were incubated in a 37 ˚C 5% CO incubator for 10 minutes. Following 
incubation, samples were washed twice.  
2.7 Phosphoflow cytometry 
Phosphoflow cytometry protocols were established by a previous member in the lab. 
Basic principles are described here, however, optimisation was part of my research 
(Results, Figures 3.3-3.10). Phosphoflow cytometry was performed in conjunction with 





Following BD Cytofix fixation, samples requiring intracellular staining were 
permeabilised with 0.5X phosphoflow permeabilisation buffer IV (BD BioSciences, 
California, USA) and incubated on ice for 30 minutes in the dark. Samples were 
washed twice with FACS buffer.  
Intracellular staining  
Samples were stained with intracellular phosphoantibodies (Table 2.2, Table 2.3) 
following permeabilisation. Phospho-antibodies recognise the phosphorylated 
epitopes listed in Table 2.2 and Table 2.3. A staining master mix with appropriate 
antibodies was prepared using FACS buffer.  Samples were stained with 25 µL master 
mix on ice for 30 minutes in the dark. Samples were washed twice.  
2.8 Data acquisition  
Stained samples were transferred from 96 well plate to FACS tubes and resuspended 
in 200uL FACS buffer. Flow cytometry and phosphoflow data acquisition was 
completed using LSR Fortessa Cell Analyser (Becton Dickinson) with the FACSDiva 
Software Version 8.0 (Becton Dickinson).  
2.9 Data analysis 
Flow cytometry data was exported from FACSDiva as .fcs files. Files were analysed 
using FlowJo 10.7.2 (FlowJo, LLC., Ashland, Oregon, USA). Histograms for the 
expression of each intracellular marker were generated by FlowJo, showing the 
number of cells expressing a certain level of phosphorylated protein.  
Mean fluorescence intensity (MFI) was calculated by FlowJo using geometric mean. 




for the expression of phosphorylated intracellular protein. This shows the effect of 
stimulation on phosphorylated protein expression relative to basal phosphorylation 
levels. The calculation is as follows: 




Early Bird software (cytoanalytics, 2014) was used to visualise individual patient 
characteristics and parameters.  
2.10 Statistical analysis  
GraphPad Prism 8.2.1 (GraphPad Software, Inc., San Diego, California, USA) was 
used to create graphs. Significance was analysed using a Mann-Whitney U test for 
non-parametric, independent data with the significance value set at p<0.05.  














Antibody Fluorophore Clone Isotype Clonality  Dilution  Company  
CD4 BV421 RPA-T4 Mouse IgG1 Monoclonal 1:80 BioLegend 
Catalogue #300532 
CD4 BV605 OKT4 Mouse IgG2b Monoclonal 1:160 BioLlegend 
Catalogue #317438 
CD3 BV785 UCHT1 Mouse IgG1 Monoclonal 1:80 BioLegend 
Catalogue #300472 
CD3 BV510 OKT3 Mouse IgG2a Monoclonal 1:80 BioLegend 
Catalogue #317332 
CD8 Alexa Fluor 
700 
RPA-T8 Mouse IgG1 Monoclonal 1:160 BioLegend 
Catalogue #301028 
CD8  PeCy5 RPA-T8 Mouse IgG1 Monoclonal 1:80 BD Sciences 
Catalogue #555368 
CD14 BV421 M5E2 Mouse IgG2a Monoclonal 1:80 BioLegend  
Catalogue #301830 





Table 2.3 Antibodies used for the staining of intracellular phosphorylated proteins 
Antibody Fluorophore Phosphorylation  
  site 
Clone Isotype Clonality  Dilution  Company  
P-p38  PerCP-
eFluor710 
Thr180, Tyr182 4NIT4KK Mouse 
IgG2b 
Monoclonal 1:80 ThermoFisher 
Catalogue  
#46-9078-41 
P-ERK1/2  PE-eFlour    
610 
Thr202, Tyr204 MILAN8R Mouse 
IgG1 
Monoclonal 1:640 ThermoFisher 
Catalogue  
#61-9109-41 
P- NFĸBp65 eFlour 660 Ser529 B33B4WP Mouse 
IgG2a 
Monoclonal 1:80 ThermoFisher 
Catalogue #50-
9863-41 
P-JNK  PE T183,Y185 N9-66 Mouse 
IgG1 
























NA= Not applicable 
Antibody  Fluorophore Phosphorylation 
site  
Clone Isotype Clonality Dilution Company 
p38 MAPK PerCP-
eFluor710 
Thr180, Tyr182 4NIT4KK Mouse 
IgG2b 





PE-eFlour 610 Thr202, Tyr204 MILAN8R Mouse IgG1 Monoclonal 1:640 ThermoFisher 
Catalogue #61-
9109-41 
NFkB-p65 eFlour 660 Ser529 B33B4WP Mouse 
IgG2a 
Monoclonal 1:80 ThermoFisher 
Catalogue #50-
9863-41 
CD14 BV421 NA M5E2 Mouse 
IgG2a 
Monoclonal 1:80 BioLegend  
Catalogue 
#301830 
CD64 FITC NA 10.1 Mouse IgG1 Monoclonal 1:40 BioLegend 
Catalogue 
#305006 
CD3 BV510 NA OKT3 Mouse 
IgG2a 
Monoclonal 1:80 BioLegend 
Catalogue 
#317332 
CD4 BV605 NA OKT4 Mouse 
IgG2b 







3.1 Basic flow cytometry  
Flow cytometry is a useful method for detecting cell surface proteins and intracellular 
proteins, thus defining the phenotype and function of cells at a single cell level. To 
understand basic principles of flow cytometry, I performed surface staining of PBMCs. 
This assisted my understanding of compensation and how to use fluorescence-minus-
one (FMOs) controls to gate populations accurately. 
Extracellular staining for CD3+, CD4+, CD8+ lymphocytes 
Frozen PBMCs from a healthy donor were defrosted. Viability, CD3, CD4 and CD8 
staining was performed and analysed by flow cytometry (Figure 3.1).  
Viability staining was important to exclude dead cells from analysis. Dead cells 
become more autoflourescent and may bind anitbody nonspecifically, increasing 
background staining (54). A live/dead control was used to ensure accurate gating on, 
or inclusion of, live cells and exclusion of dead cells.  
Fluorescently labelled antibodies specific to surface proteins allowed visualisation of 
CD3+ CD4+ and CD3+ CD8+ T cell populations and the proportions of these 
populations as a percentage of total CD3+ cells. 42.1% were CD3+ CD4+ T cells and 
47.5% were CD3+ CD8+ T cells (Figure 3.1). A repeat of this experiment on the same 
donor yielded similar results; 43.2% CD3+ CD4+ T cells and 49.9% CD3+ CD8+ T 
cells, showing consistent experimental technqiue and controls (Appendix 7.1). FMO 
controls and an unstained control were used to guide the gating of populations. An 




Figure 3.1 FMOs were used to guide gating of CD3+ CD4+ and CD3+ CD8 
T cells populations. A healthy PBMC sample was defrosted and stained with 
fluorescently labelled antibodies and fixed with PFA. FMOs were stained for all 
fluorescent antibodies except 1, as indicated, and fixed with PFA. Live cells 
were previously gated on PBMCs. CD3+ CD4+ and CD3+ CD8+ populations 





This allows visualisation of where the negative population is positioned for the 
excluded antibody, relative to the emission of other fluorescent anitbodies (Figure 3.1). 
It also allows assessment of any potential spill over and/or compensation error.  Spill 
over refers to when a fluorophore’s emission spectra is larger than what is detected 
by a filter. As a result, one fluorophore’s emission may ‘spill over’ into another detector, 
not specific to that fluorophore. Compensation is applied to account for this, allowing 
accurate detection of specific proteins.  
Prior to specific population gating, all samples were subjected to preliminary gating for 










Figure 3.2 Preliminary gating on PBMCs. Data acquired from LSR BD Fortessa 
were imported into FlowJo software for analysis. Prior to population gating, cells 
were gated on PBMCs. Time gating and two singlet gates were applied to remove 
cell doublets and contamination. PBMCs were then isolated using side scatter and 




If there was disrupted acquisition at the time of sample analysis, this could have 
implied a blockage, contamination or an issue with the gas pressure. Time gating 
allowed exclusion of disrupted acquisition. Singlet gating was performed twice using 
side scatter and forward scatter height and area variables. Side scatter increases with 
cell density and forward scatter increases with cell size. Therefore, singlet gates 
remove cell doublets and/or potential red blood cell contaminiation based on size. The 
PBMC population was distinguished by cell size and density, using side scatter and 
forward scatter variables. Figure 3.1 and Figure 3.2 provide a basis for how I gated on 
PBMCs and used appropriate controls for identifiying specific cell populations.  
3.2 Optimisation of phosphoflow cytometry 
Signalling cascades involve phosphorylation of multiple proteins. With specific 
reference to the TNF pathways discussed in the present study, phosphorylation is 
indicative of an ‘activated’ protein. Phosphoflow cytometry refers to a method of 
cytometry dedicated to identifying and quantifying the expression of phosphorylated 
proteins at a single cell level. Therefore, phosphoflow cytometry can inform which 
signalling pathways are activated in response to stimuli. Combined with surface 
staining as discussed above, I could determine the expression of phosphorylated 
signalling proteins in specific cell types. 
Despite its value, phosphoflow cytometry has proven to be technically difficult. 
Phosphorylation is a transient biological event which can be affected by in vitro culture 
stress and technique (55). Identifying the optimal conditions to induce and capture 






My optimisation protocol was separated into four sections (Figure 3.3). Each section 
was investigated as an independent optimisation step. First, the appropriate 
concentration for permeabilisation buffer, 1X or 0.5X, was determined and phospho-
antibodies were titrated. 
 
Figure 3.3 Diagram showing work flow for optimisation of phosphoflow cytometry 
protocol.  
To optimise in vitro TNF stimulation, I investigated the length of stimulation and the 
effect of resting cells prior to stimulation to reduce basal phosphorylation. 
PMA/Ionomcyin stimulation was used as a comparison against TNF stimulation and 
an indicator of the general inflammatory potential of signalling pathways not directly 
linked to TNF-receptor binding. Lastly, I compared the use of stimulated frozen PBMCs 
and stimulated fresh PBMCs and the effect either condition had on the fold change of 
phosphorylated protein expression. 
Titrations for phosphoflow antibodies ensured accurate identification of 
positive populations  
Titrations were an important component of panel optimisation, as optimal antibody 
concentrations achieve better staining resolution. Excess quanitities of low affinity 
antibody can lead to high background staining and confound interpretation of flow 
cytometry data (i.e. increase false positives) (55). Titration determines the optimal 












nonspecific/background staining. The most appropriate titration is the one which had 
most separation between the MFI of the positive population and the MFI of the 
negative population. The separation index (SI) value allowed quantification of this 
separation.Titrations with less distinguishable separation (low SI) have a risk of 
including negatively expressing cells in the positive gate. When titrating phospho-
antibodies, these positive and negative populations may be less defined due to their 
varied expression within a population. In this case, the SI value was useful. Titrations 
of surface antibodies were previously performed by lab members, whereas I titrated 
the specific phospho-anitbodies in the finalised phosphoflow cytometry panel (Table 
2.4). 
Samples were stimulated with TNF in order to visualise phosphorylated proteins along 
the TNF signalling pathway. A 5 step 2-fold dilution series was performed, starting 
from the manufacturer’s recommended concentration. All titrations, excluding JNK, 
showed ‘smeared’, rather than strictly defined, positive and negative populations, as 
expected (Figure 3.4). Therefore the SI value was used to determine the optimal 
concentration. The anti-NFĸBp65 eFluor660 antibody showed most separation at the 
1:40 dilution (SI=5.94). The anti-ERK PE eFluor610 anitbody showed most separation 
at the 1:640 dilution (SI=1562). The anti-p38 perCP eFluor710 anitbody showed most 
separation at either the 1:40 or 1:80 dilution (SI=0.04, SI=0.04 respectively); given no 
difference between the two SI values, I proceeded with the 1:40 dilution following this 
experiment. 
Unexpectedly, no positive populations for phosphorylated JNK was detected by the 
anti-JNK PE antibody at any dilution. This may have been because no dilutions tested 






















A  B 
C D 
Figure 3.4 Titrations for phosphoflow cytometry antibodies with tested dilution 
factor and separation index value. Frozen healthy PBMCs were stimulated with 
100ng/mL recombinant TNF for 15 minutes and stained with different concentrations of 
intracellular phospho-antibodies. Titrations of (A) anti-p38 conjugated to PerCp 
eFluor710, (B) anti-ERK conjugated to PE-eFluor 610, (C) anti-NFkBp65 conjugated to 
eFluor66, (D) anti-JNK conjugated to PE. Most appropriate dilution factor is in bold. Data 
was concatenated using FlowJo software. Separation index values were calculated using 
FlowJo software. DF= dilution factor, SI = separation index value, US = Unstained 
control.   
 
Figure 3.5 Titrations for phosphoflow cytometry antibodies with tested dilution 
factor and separation index value. Frozen healthy PBMCs were stimulated with 
100ng/mL recombinant TNF and stained with different concentrations of intracellular 
phosphoantibodies. Titrations of (A) anti-p38 conjugated to PerCp efluor710, (B) anti-
ERK conjugated to PE-efluor 610, (C) anti-NFkB-p65 conjugated to efluor66, (D) anti-
JNK conjugated to PE. Most appropriate dilution factor is in bold. Data was concatenated 
using FlowJo software. Separation index values were calculated using FlowJo.  DF= 





for inducing phosphorylation of JNK, or the antibody was failing to bind the 
phosphoepitope. To investigate whether the antibody was working to bind 
phosphoepitopes, the titration experiment was repeated on PBMCs stimulated with 
PMA/ionomycin, as opposed to TNF (Figure 3.9).  
Permeabilisation buffer concentration did not affect P-NFĸBp65 expression 
Permeabilisation buffer creates holes in the cell membrane, causing the cell to become 
porous, therefore allowing intracellular antibody to enter and bind to target proteins. 
The permeabilisation buffer purchased specifically for phosphoflow has a stock 
concentration of 10X, which should be diluted prior to use. The manufacturer showed 
a decrease in cell viability and reduced detection of surface proteins at the 1X 
concentration, compared to lower concentrations (56). At 0.5X, intracellular 
phosphorylated protein expression was reduced compared to the 1X concentration. 
Therefore, the 0.5X and 1X concentrations were compared in a phosphoflow 
cytometry experiment to determine whether concentration would affect the magnitude 
of phosphorylated protein expression in response to stimulation (Figure 3.5).  PBMCs 
from a healthy donor were stimulated with recombinant TNF for 15 minutes, fixed and 
stained intracellularly for detection of P-NFkBp65. There was no difference between 
0.5X (light pink histogram, Figure 3.5) and 1X (red histogram, Figure 3.5) 
concentrations on the detection of phosphorylated NFĸBp65, as indicated by identical 
rightward shifts in fluorescence intensity. Therefore, the 0.5X concentration was used 
in future experiments. The 0.5X concentration detected similar changes in 
phosphorylated protein expression compared to 1X, but was also less likely to impair 






Figure 3.5 Permeabilisation buffer concentration did not affect phosphorylated 
NFĸBp65 expression. Frozen PBMCs from a healthy donor were defrosted, stimulated with 
recombinant TNF and fixed. PBMCs were split into two independent wells after fixation. One 
sample was incubated with 0.5X (light pink) permeabilisation buffer concentration (n=1), 
whilst the other sample was incubated with 1X (dark pink) permeabilisation buffer 
concentration (n=1). After 30minutes, both samples were intracellularly stained with anti-P-
NFĸBp65 antibody conjugated to eFluor660. Histogram shows fluorescence intensity of 
stimulated samples indicating P-NFĸBp65 expression, relative to an unstained control. Data 




3.3 Optimising in vitro TNF stimulation  
When cells are at rest p38, NFĸBp65 and ERK pathways are likely to be 
unphosphorylated or deactivated. To induce phosphorylation, cells need to receive 
signals as they would in the body. Parameters of stimulation, such as stimulus 
concentration, stimulation length and environmental conditions (temperature, light) are 
important to ensure activation and capture the kinetics of cell signalling.  
15-minute in vitro stimulation with recombinant TNF yielded a larger fold change 
of P-NFĸBp65 MFI compared to a 30-minute stimulation 
15-minute and 30-minute TNF stimulation time points were chosen for comparison, as 
these were previously shown to induce MAPK and NFĸBp65 phosphorylation (57, 58). 
Frozen healthy PBMCs were stimulated for 0, 15 minutes or 30 minutes with 100ng/mL 
TNF, then stained for P-p38, P-NFĸBp65, P-ERK expression. PBMCs showed 
increased phosphorylation of all three proteins, in response to stimulation (MFI fold 
change greater than 1), following both 15-minute and 30-minute stimulations (Figure 
3.6). P-ERK expression, however, did not differ substantially between the 15-minute 
stimulation (1.04-fold change in MFI) or 30-minute stimulation (1.08-fold change in 
MFI). P-p38 expression following the 30-minute stimulation elicited a 1.82-fold change 
in MFI, compared to a 1.58-fold change in MFI following the 15-minute stimulation. P-
NFĸBp65 expression increased by a 1.18-fold change in MFI following the 15-minute 
stimulation but decreased (0.94-fold change in MFI) following the 30-minute 













If I wanted to stimulate PBMCs for 30 minutes to achieve optimal phosphorylated p38 
expression, but 15 minutes to achieve optimal phosphorylated NFĸBp65 expression, I 
would have had to split my panel. This means I would have to split my sample so I 
could stimulate for different time points, and then stain accordingly. Given time 
restrictions, I wanted to avoid splitting my panel as this would increase variability. 
Provided I was working with patient samples which I received on different days and 
were therefore independent experiments, I did not want to increase variability further. 
The 15-minute stimulation worked for phosphorylated ERK and NFĸBp65 expression. 
Figure 3.6 Effect of the length of TNF stimulation on the fold change  
of phosphorylated protein MFI. Frozen PBMCs from a healthy donor were defrosted 
and split into three samples. Each sample was stimulated with 100ng/mL recombinant 
TNF for either 0 minutes (unstimulated control), 15 or 30 minutes. Samples were stained 
for intracellular phosphorylate proteins p38, ERK and NFĸBp65. The MFI fold change 
was calculated for the 15-minute stimulated sample and the 30-minute stimulated 
sample, relative to the unstimulated control. Data from two independent experiments; 




Although the 15-minute stimulation did not yield the largest change in phosphorylated 
p38 expression, there was substantial fold change following the 15-minute stimulation; 
therefore, I decided to continue with 15-minute stimulations for future experiments. 
Specific cell types may have responded to in vitro TNF stimulation differently  
PBMCs were subdivided into lymphocytes and monocytes by using forward scatter 
and side scatter characteristics in flow cytometry gating (Figure 3.7A). Lymphocytes 
are smaller and have less granularity/density than monocytes, and therefore have less 
forward and side scattering of light. It was observed that the monocytic population had 
a larger rightward shift in fluorescence intensity relative to the unstimulated control, 
than that observed in the lymphocyte population, indicating a larger increase in P-p38 
expression. (Figure 3.7B). 
 
Figure 3.7 Monocytes showed a larger shift in phosphorylated p38 expression than 
lymphocytes. PBMCs were stimulated with TNF and stained for phosphorylated p38 
expression. (A) Side scatter and forward scatter gating was used to isolate monocytic and 
lymphocytic populations. (B) Histogram showing fluorescence intensity indicative of 
phosphorylated p38 expression. Shift in stimulated lymphocytes was visually compared to 







Resting cells prior to stimulation had no effect on the fold change of P-NFĸBp65 
MFI 
Small fold changes between unstimulated and stimulated conditions may be explained 
by cell samples having high basal phosphorylation due to in vitro stress. 
NFĸBp65 can be phosphorylated in response to physical stress (35). Similarly, p38 is 
a stress MAPK, phosphorylated in response to cell damage/stress. Therefore, as 
suggested by literature (55), cells were rested  prior to stimulation in attempt to 
equilibrate cells under in vitro conditions. In three independent experiments, cells were 
rested in U-well plates, in a 37°C incubator for either 1 hour, 4 hours or not rested (0 
hours). There was no substantial difference in the fold change in MFI between groups 














3.4 Stimulation with PMA/ionomycin  
The initial rationale for using PMA/ionomycin stimulation was to determine whether the 
anti-P-JNK antibody was identifying phosphoepitopes of JNK. PMA/ionomycin 
stimulation was also used to compare protein phosphorylation to TNF stimulation-
induced phosphorylation. PMA/ionomycin is a general stimulant, which bypasses the 
need for receptor activation by causing an influx of calcium within the cell (59, 60). 
Figure 3.8 Resting cells prior to stimulation had no impact on the fold change 
of phosphorylated NFĸBp65 MFI. Frozen PBMCs were defrosted, suspended in 
RPMI, and rested in a 37°C incubator for either 1 or 4 hours. The no-rest condition 
was used in phosphoflow cytometry experiment immediately after the defrosting 
process. All samples underwent a standard phosphoflow cytometry protocol after rest 
time and stained for intracellular P-NFĸBp65. Data from three independent 
experiments (n=1 for each independent experiment).  
 
 
Figure 3.7 Resting cells prior to stimulation had no impact on the MFI fold 
change of phosphorylated NFĸBp65 expression. Frozen PBMCs were defrosted, 
suspended in RMPI and rested in a 37°C incubator for either 1 or 4 hours. The no-
rest condition was used in phosphoflow cytometry experiment immediately after 
defrosting process. All samples underwent standard phosphoflow cytometry protocol 
after rest time and stained for intracellular P-NFĸBp65. Data from three independent 
experiments (n=1 for each independent experiment).  
 
 
Figure 3.7 Resting cells prior to stimulation had no impact on the MFI fold 
change of phosphorylated NFĸBp65 expression. Frozen PBMCs were defrosted, 
suspended in RMPI and rested in a 37°C incubator for either 1 or 4 hours. The no-
rest condition was used in phosphoflow cytometry experiment immediately after 
defrosting process. All samples underwent standard phosphoflow cytometry protocol 
after rest time and stained for intracellular P-NFĸBp65. Data from three independent 






Conditions of PMA/stimulation were determined by literature, which suggested a ~15-
minute stimulation at concentration of 50ng/mL PMA and 50ng/mL ionomycin (61). 
The anti-P-JNK antibody detected phosphoepitopes of JNK in response to 
PMA/ionomycin stimulation  
PBMCs were stained with 1:100 anti-P-JNK antibody, as previously used (62), to verify 
its functionality. Both unstimulated and stimulated samples displayed positive P-JNK 

















Figure 3.9 PMA/ionomycin stimulation did not result in increased 
phosphorylation of p38. Frozen healthy PBMC samples were defrosted and 
stimulated with 50ng/mL PMA and 50ng/mL ionomycin for 15 minutes in a 37°C 
incubator. Samples were then fixed and stained intracellularly for phosphorylated (A) 
p38, (B) NFĸBp65 (C) JNK, (D) ERK using titrated dilutions previously determined. 
The anti-JNK antibody was used at a 1:100 dilution. Histogram showing fluorescence 




This result proves that the antibody works to identify phosphoepitopes of JNK, 
suggesting that TNF stimulation was failing to induce JNK phosphorylation or the 
dilution factors were not appropriate.  
PMA/ionomycin stimulation did not cause an increase in phosphorylated p38 
expression 
For both phosphorylated NFĸBp65 and ERK expression (Figure 3.9B, 3.9D), there 
was an increase following stimulation when compared to the unstimulated control, as 
indicated by a rightward shift in fluorescence intensity. Unexpectedly, there was a 
decrease in phosphorylated p38 expression following stimulation, compared to the 
unstimulated control. 
3.4 Measuring stimulation of fresh PBMCs compared to frozen 
PBMCs 
A study by Chen and authors (2010) (63) found in vitro stimulation of fresh PBMCs 
with LPS improved cell viability, and induced a higher MFI of TNF gene expression. 
Given phosphoflow is a sensitive assay but fresh patient samples were limited, this 
prompted investigation into whether phosphorylated protein expression would differ 
between fresh and frozen PBMCs (Figure 3.10). PBMCs were isolated from the same 
donor. One sample was taken a week prior to experimentation, cryopreserved, and 
stored in the liquid nitrogen. On the day of experimentation, this sample was defrosted, 
and a fresh blood sample was processed. Following TNF stimulation, samples were 
fixed and stained for extracellular and intracellular proteins of interest.  
When comparing the expression of surface markers (Figure 3.10A), CD3 (lymphocyte 
marker) and CD64 (monocyte marker), showed little difference between proportion of 




PBMCs from the fresh PBMC sample, compared to 54.4% from the frozen sample. 
Similarly, 6.78% and 11.1% of CD64 positive cells as a proportion of live PBMCs were 
isolated from the fresh and frozen samples, respectively. Changes in the MFI fold 
change of phosphorylated, intracellular proteins, however, did vary substantially for 
phosphorylated ERK and NFĸBp65 expression (Figure 3.10B). Fresh PBMCs 
stimulated with PMA/ionomycin exhibited a 6-fold increase in phosphorylated 
NFkBp65 MFI compared to a ~3-fold increase observed in response to frozen PBMC 
stimulation. Similarly, phosphorylated ERK MFI increased by 9-fold following fresh 
PBMC PMA/ionomycin stimulation, compared to a 6-fold increase in frozen PBMCs. 
MFI fold change following TNF stimulation was also increased in fresh PBMC samples 
compared to frozen; however, the extent of this was less than PMA/ionomycin 
stimulation. Fresh PBMCs stimulated with TNF showed a ~2 fold increase in 
phosphorylated ERK expression, compared to no change (MFI fold change of 1) 
observed in the frozen TNF-stimulated PBMC sample. Phosphorylated NFĸBp65 MFI 
fold changes were similar, with a ~2 fold increase and no change, in fresh and frozen 
samples, respectively. Phosphorylated p38 MFI expression was minimally affected by 
either stimulation, with a decreased MFI compared to the unstimulated control (MFI 
less than 1) observed in response to PMA/ionomycin stimulation, in both fresh or 
frozen samples (Figure 3.10B). This corroborates results seen in figure 3.8, where 
PMA/ionomycin failed to increase phosphorylation. TNF stimulation yielded a 1.2-fold 
change in MFI in fresh PBMC samples, compared to a 1.1-fold change in the frozen 
sample. Irrespective of stimulant, fresh PBMCs yielded larger fold changes in MFI than 











Figure 3.10 Stimulation of fresh samples are optimal for detecting changes in 
phosphorylated protein MFI. Blood samples were collected from the same donor at different 
times. One sample was frozen ~1 week prior to experimentation. Fresh sample acquired on 
day of experimentation. Both samples were stimulated with TNF and PMA/ionomycin and 
stained for extracellular proteins and intracellular phosphorylated proteins. (A) Flow cytometry 
gating of CD3+ and CD64+ cells in fresh (left) and frozen (right) samples stimulated with TNF. 
Statistic of each gate shows cell proportion of parent population (PBMCs). (B) MFI fold change 
quantification of intracellular phosphorylated protein expression for TNF or PMA/ionomycin 





3.5 Investigation of signalling pathways in IBD 
 
Comparing HC and IBD groups 
The optimised phosphoflow cytometry protocol was then used to investigate the 
expression of activated TNF signalling proteins in response to either TNF or 
PMA/ionomycin stimulation. PMA/ionomycin stimulation was used to determine the 
inflammatory capacity of pathways irrespective of TNF-receptor binding.  
IBD patients are reported to have upregulated TNF in serum compared to HCs (20, 
23). To validate this with respect to TNF’s downstream signalling pathways, PBMCs 
from healthy individuals (n=8 from 2 independent experiments) and 5 IBD patients 
over the course of two months (independent experiments) were isolated and stained 
with a full phosphoflow panel (Table 2.4). Phosphorylation of p38, ERK and NFĸBp65 
proteins in response to TNF and PMA/ionomycin stimulation was observed.  
There were no significant differences (p>0.05) in P-p38, P-ERK or P-NFkBp65 
expression in PBMCs isolated from IBD and healthy individuals (Figure 3.11). This 








Given monocytes may have been responding differently to stimulation, CD14+CD64+ 
monocyte and CD3+ CD4+ T cell antibodies were used to isolate (Figure 3.11) and 











Given monocytes may have been responding differently to stimulation (Figure 3.7), 
CD14+ CD64+ monocyte and CD3+ CD4+ T cell markers were used to distinguish T 
cells and monocytes to investigate their protein expression in IBD and healthy groups 
(Figure 3.12).  
                         P-p38                       P-ERK                   P-NFĸBp65 
Figure 3.11 Fold change in phosphorylated protein MFI in HC group and IBD group. PBMCs 
were isolated from healthy individuals and IBD patients. PBMCs were stimulated with 100ng/mL 
TNF (A) or 50ng/mL PMA, 50ng/mL ionomycin (B) and were stained with surface and intracellular 
antibodies at titrated concentrations. Left panel shows P-p38 fold change in MFI. Centre panel 
shows P-ERK fold change in MFI. Right panel shows P-NFĸBp65 fold change in MFI. Box plot 
representing distribution of groups. Line indicates median MFI expression, with upper and lower 
limits indicating the minimum and maximum MFI fold changes observed. NS=not significant. Non 
significance determined by Mann-Whitney U test (p>0.05). HC = healthy controls (n=8 for p38 
and ERK analysis, n=2 for NFkBp65 analysis). IBD = inflammatory bowel disease patients (n=5 





There were no significant differences in P-p38, P-ERK or P-NFĸBp65 expression in 
either T cells or monocytes between HC and IBD groups (Figure 3.13). This result was 




Figure 3.12 Gating strategy used to identify CD4+ T cell populations and CD14+CD64+ 
monocyte populations. Live PBMCs were isolated after time and singlet preliminary gating 
using the forward scatter and side scatter variables. CD3 positive and negative populations 
were isolated from live PBMCs. CD3+ CD4+ cells were gated on to establish CD4+ T cell 
populations. CD3- CD14+ CD64+ cells were gated on to establish monocytic populations. 


















                         P-p38                         P-ERK                      P-NFĸBp65 
Figure 3.13 Phosphorylated protein fold change in MFI in HC and IBD T cells and 
monocytes. PBMCs were isolated from healthy individuals and IBD patients. PBMCs were 
stimulated with 100ng/mL TNF (A) or 50ng/mL PMA, 50ng/mL ionomycin (B) and were 
stained with surface and intracellular antibodies at appropriate concentrations. Using FlowJo 
software, surface proteins were used to identify monocyte and T cell populations for analysis. 
Left panel shows P-p38 MFI fold change. Centre shows P-ERK MFI fold change. Right panel 
shows P-NFĸBp65 MFI fold change. Box plot representing distribution of groups. Line 
indicates median MFI expression, with upper and lower limits indicating the minimum and 
maximum MFI fold changes observed. HC = healthy controls (n=8 for p38 and ERK analysis, 
n=2 for NFkBp65 analysis). IBD = inflammatory bowel disease patients (n=5 for p38 and ERK 
analysis, n=2 for NFkBp65 analysis). NS=not significant. Non significance determined by 




Originally this panel included a CD8+ T cell marker. In a practice experiment staining 
two frozen IBD samples, an anti-CD8 antibody conjugated to a PE Cy5 fluorophore 
was added to the phosphoflow cytometry panel (Table 2.4). A potential compensation 
issue was observed, which may have resulted in fluorescent spill over into the p38 
channel (Figure 3.14). Upon analysing P-p38 expression within the CD3+ CD8+ 
population, the histogram showed multiple peaks of expression which did not intuitively 
look like different cell populations (Figure 3.14A). Upon analysis of the p38 FMO 
(Figure 3.14C), evidence of spill over was observed by the absence of a single peak; 
a single peak usually indicates a negative signal of expression for this fluorophore, 
which is anticipated in an FMO. Therefore, the presence of multiple peaks at different 
fluorescent intensities indicates spill over from another fluorophore’s emission spectra.  
Figure 3.14 CD8 conjugated to the PeCy5 fluorophore caused compensation issues 
and potential spill over into the p38 channel. Two frozen IBD samples were processed 
and stained extracellularly and intracellularly. (A) p38 expression in cells gated as CD3+ 
CD8+ T cells. Grey histogram is the unstained control. Blue histogram is the unstimulated 
control. Red is the TNF stimulated sample. Green is the PMA/ionomycin stimulated 
sample. (B) Image from compensation matrix showing p38 channel and CD8 channel for 






Observed in the manual compensation matrix accessible via FlowJo, shown in figure 
3.14B, the oblong-shape indicates potential over-compensation. I attempted altering 
the compensation matrix manually to correct this, but this then interfered with the 
compensation of other channels. Therefore, there may have been over-compensation 
on the LSR Fortessa during compensation set up, which then becomes more difficult 
to manually fix. A student from the Kemp lab also had a problem with the compensation 
of this specific antibody and fluorophore (CD8 PeCy5) previously, and omitted it from 
their phosphoflow cytometry panel (64). Therefore, in the interest of time and the 
limited space in my flow cytometry panel, I decided to exclude a CD8 marker. 
Two IBD patients show signalling heterogeneity  
Despite no significant differences in phosphorylated protein expression between 
healthy and IBD groups, analysing differences between individual IBD patients allowed 
investigation of individual heterogeneity. To show individual protein expression, the 
same IBD data from Figure 3.12 is presented here in a scatter plot as opposed to a 
box plot (Figure 3.15). There were two patients of interest which have substantially 
different phosphorylated protein expression relative to other IBD patients. One patient 
(Figure 3.15.B, bottom left, coloured red) showed a ~4 fold increase in phosphorylated 
p38 expression in PMA/ionomycin stimulated CD3+ CD4+ T cells. Other IBD and 
healthy individuals showed little to no change from basal phosphorylation levels of 
p38. This patient also had a ~2 fold change increase in P-NFĸBp65 expression in 
PMA/ionomycin stimulated T cells, which was low comparative to the other IBD patient 
analysed (Figure 3.15B, bottom right, coloured red). The other IBD patient had a ~6 
fold increase in P-NFĸBp65 expression (Figure 3.15B, bottom right, coloured green). 




protein measured in response to TNF stimulation (Figure 3.15A). Blue coloured data 
points represent frozen samples which may had been impacted by the compensation 













Figure 3.15 Two IBD patients showed different MFI fold changes in PMA/ionomycin 
stimulated CD3+ CD4+ T cells. Same data shown in figure 3.12 but presented on scatter 
plots to show individual protein expression. MFI fold change in response to (A) TNF 
stimulation or (B) PMA/ionomycin stimulation. Left panel shows P-p38 MFI fold change. 
Centre shows P-ERK MFI fold change. Right panel shows P-NFĸBp65 MFI fold change  
Blue coloured data points represent frozen samples. Red and green data points represent 
patients of interest. 




One patient of interest was an anti-TNF non-responder  
The same data from Figure 3.14 was then plotted on an Early Bird graph, which allows 
the comparison of multiple parameters of individuals (Figure 3.16). Here, the plot 
correlates signalling pathway expression with individual treatment status. These 
patients were representative of both sexes and ages ranging from 29 to 63 (Table 2.1). 
Four patients were not on any anti-TNF treatment, nor had they been recorded to have 
been in the past. These patients were instead being treated with 
immunosuppressants. Interestingly, patient 3 who was observed to have 
comparatively high P-p38 and P-NFĸBp65 expression was the only patient to have 
had been on an anti-TNF. At the time of this experiment, the patient was being treated 
with Humira but not responding to it. In the past this patient had been treated with 
Infliximab.  
The Early Bird graph correlated the TNF signalling expression of each protein and 
stimulant to show heterogeneity. Most of these patients are exhibiting minor 








Figure 3.16 Correlations between TNF signalling protein expression and treatment status of individual IBD patients. Same data as shown 
in figure 3.10 and 3.12. Phosphorylated protein expression in T cells (A) or monocytes (B) response to TNF stimulation (t) or PMA/ionomycin 
stimulation (p). For each individual patient (patients 1,2,3,4 and 5) a line is used to visually correlate treatments (treatment 1 and 2), anti-TNF 
response and the TNF signalling profile of either (A) T cells (B) or monocytes. Orange line in both A and B represent anti-TNF non-responder 








4. Discussion  
The overall aim of this study was to investigate the potential TNF signalling 
heterogeneity between HC and IBD groups, but particularly within the IBD cohort. 
From these results, the aim was to identify any substantial differences in 
phosphorylated protein expression in response to stimulation, exhibiting the 
inflammatory potential of TNF signalling. The investigation of downstream TNF 
signalling proteins in HC and IBD cohorts required optimisation of a phosphoflow 
cytometry protocol.   
4.1 Statistical Analysis  
It is important to acknowledge that caution is required when interpreting the statistical 
analysis due to a low sample size. A non-parametric test was used to account for low 
sample size and therefore inability to predict normality. The sample size for NFĸBp65 
analysis was two for IBD patients and five for HCs; therefore, no statistical analysis 
was performed.  
4.2 Overview of Results  
IBD treatments may confound naïve differences in signalling pathways between 
HC and IBD groups 
To investigate the differences in TNF signalling protein expression between HCs and 
IBD, PBMCs were stimulated with TNF or PMA/ionomycin which allowed visualisation 
of phosphorylated p38, NFĸBp65 and ERK expression. Phosphorylated protein 
expression in PBMCs stimulated with TNF or PMA/ionomycin stimulation did not differ 
significantly between the HC and IBD groups (Figure 3.11). Similarly, when PBMCs 




between HC and IBD groups (Figure 3.13). This was unexpected given TNF is 
upregulated in the serum and mucosa of IBD patients (23). There is evidence 
supporting that phosphorylated MAPKs and NFĸBp65 are upregulated in IBD patients 
compared to HCs, but these studies are often not linked to what the pathways are 
doing functionally. Despite similar protein levels between groups perhaps these 
proteins could be functioning differently between groups. This is substantiated by the 
knowledge that these proteins have been implicated in IBD pathogenesis, for eliciting 
pro-inflammatory cell responses (40, 41).  
Additionally, patient information received post-analysis revealed that all IBD patients 
in this cohort were being treated with immunosuppressants, which may explain 
suppressed inflammatory signalling pathways and therefore similarity to the HC group. 
Most IBD patients were presumed to be in an active period of disease, or undefined if 
clinical notes were unclear (Table 2.1). IBD patients in this cohort were being treated 
with thiopurines, mesalazine and/or glucocorticoids. These immunosuppressants do 
not directly target TNF, but work generally to reduce inflammatory pathways (65-68); 
however, limiting this hypothesis is the absence of information regarding dose 
regimens of each patient and whether the drugs described here were bioactive at the 
time blood samples were taken. Patients 1, 2, 3 and 4 were being treated with 
thiopurines, 6-Metacarptopurine (6MP) and azathioprine. Azathioprine is a prodrug, 
becoming its activated form, 6MP, upon exposure to cellular environments (65). 6MP 
can be converted into metabolites 6-thioguanine nucleotides (6TGN) and 6-
thioguanine triphosphate (6TTP). 6TNs are incorporated into cellular nucleic acids 
resulting in the inhibition of lymphocyte proliferation (65). 6TGNs can modulate Rac1 




activation; upon modulation by thiopurine metabolites, a costimulatory signal can be 
converted into an apoptotic signal. Increased cell death may reduce absolute quantity 
of TNF signalling proteins; however, because changes in expression in this study were 
normalised to individual basal expression by fold change, the changes in protein 
expression observed should be independent of this.  
There is some evidence of how these immunosuppressants may alter immune 
signalling pathways. Microglial cells are considered to be immune cells of the nervous 
system. Microglia treated with 6MP exhibited reduced NFĸBp65 phosphorylation and 
consequently translocation to the nucleus (70). IBD patients have been reported to 
have upregulated NFkBp65 activation and expression compared to non-IBD controls. 
Therefore, whilst there was no significant difference between HC and IBD groups, 
treatment with 6MP could be reducing NFĸBp65 expression to a physiological level 
comparable to that of the HC group.  
Treatment of trinitrobenzene sulfonic acid-induced rat colitis with azathioprine resulted 
in increased ERK expression in response to oxidative stress (71). Conflictingly, the 
data presented here disputes these findings, as ERK expression was not significantly 
increased in patients treated with 6MP or azathioprine, compared to HCs. It may be 
that a larger sample size is needed to validate these results, considering there are 
differences between mouse models of IBD and humans. 
Patient 1 was also being treated with mesalazine, with the brand name Pentasa. 
Mesalazine is part of the aminosalicyates drug group, which act directly on the 




expression in murine colon epithelial cell lines; but mesalazine does not act directly on 
immune cells.  
Evidently, a larger sample size could potentially negate confounders such as drug 
treatment. 
Individuals with IBD show signalling heterogeneity  
From the IBD cohort in this study, there were two patients of interest. Patient 3 who 
exhibited higher expression of phosphorylated p38 and lower NFĸBp65 expression in 
CD3+ CD4+ T cells compared to other IBD patients (Figure 3.15). Patient 5 showed 
higher NFĸBp65 in CD3+ CD4+ T cells than patient 3 (Figure 3.15), but similar 
expression to HCs (Figure 3.13). It should be noted that most patients were on 
mechanistically similar immunosuppressant therapies and yet heterogeneity in 
signalling within a small cohort was still observed.  
Patient 5 
Patient 5 exhibited higher phosphorylated NFĸBp65 expression in PMA/ionomycin 
stimulated T cells, compared to patient 3. Interestingly, this was similar to NFĸBp65 
expression in HCs. Given only two IBD patients were examined for phosphorylated 
NFĸBp65 expression, the difference between these two patients and whether it would 
be a true representation of a potential outlier, is inconclusive.   
At the time of sample collection, patient 5 was being treated with a glucocorticoid, 
prednisone (Figure 3.16, Table 2.1). Glucocorticoids work by binding to glucocorticoid 
receptors which can increase production of regulatory or anti-inflammatory proteins 
(67). Glucocorticoid-mediated regulatory proteins are known to reduce inflammation 




high NFĸBp65 expression in this patient. Although there is no reference to the exact 
dosing regimen for this patient, the half-life of prednisone is 3-4 hours (66), so 
potentially NFĸBp65 expression could have recovered to the high levels expected in 
an IBD patient, by the time of experimental analysis (66). Whilst high activated 
NFĸBp65 expression in IBD patients is expected, this patient’s 6-fold change in 
expression was representative of the healthy cohort (36). Therefore, it is difficult to 
determine the significance of this result without insight into the function of NFĸBp65 in 
T cells of this patient. No other signalling pathways seemed to be over- or under- 
represented compared to the remaining healthy and IBD donors, as shown in Figure 
14 and Figure 15. 
Patient 3 
Patient 3 exhibited a comparatively smaller fold change in P-NFĸBp65 expression and 
upregulated P-p38 expression in response to PMA/ionomycin stimulation. Patient 3 
was being treated with 6MP, allopurinol and has not been responding to Humira, an 
anti-TNF antibody (Figure 3.16, Table 2.1). Allopurinol works similarly to 6MP, in that 
it can switch thiopurine metabolism to produce the guanine analogues which are 
incorporated into cellular nucleic acids to inhibit immune cell proliferation (74). Patient 
3 has previously been on infliximab and was concluded to be a primary non-responder. 
Humira was reported to be initially therapeutic, but this interpretation may be 
confounded by the effects of 6MP and allopurinol. Even though there was no evidence 
of antibodies against Humira, which is sometimes hypothesised to be a mechanism of 
secondary non-response (51), patient 3 was labelled as a Humira secondary non-




and show heterogeneity compared to other IBD patients on similar 
immunosuppressants. 
As mentioned, 6MP has been shown to reduce activated NFĸBp65 expression (65). 
Therefore, the lower NFĸBp65 phosphorylation level observed in patient 3 could, 
hypothetically, be explained by 6MP treatment. However, an MFI fold change of 2 is 
substantially lower than the median of fold change observed in the HC cohort, which 
is unexpected given other signalling pathways in T cells and monocytes represented 
in patient 3 were similar to the HC group. Again, no significant conclusions can be 
made without insight into the function of NFĸBp65. 
Additionally, patient 3 exhibited a larger fold change of phosphorylated p38 expression 
in PMA/ionomycin stimulated CD3+ CD4+ T cells (Figure 3.14). This was higher than 
the expression of P-p38 of any HC or IBD patient observed. If p38 were to be 
evidenced to be upregulated in regulatory T cells in patient 3, a subset of CD4+ T cells, 
this may be explained by anti-TNF-induced expression. Anti-TNF therapy has been 
shown to increase frequency of Tregs following treatment, compared to before anti-
TNF treatment (75-77). A study found that both anti-TNF responding and non-
responding IBD patients treated with infliximab showed upregulated active p38 in T 
cells (45). Humira specifically has been found to encourage the expansion of FOXP3+ 
Tregs in the context of rheumatoid arthritis, through encouraging the interaction 
between monocytic tmTNF and Treg bound TNFR2, and this is thought to be in a 
MAPK dependent manner (76). Evidence supports the role of p38 in maintaining the 
suppressive function, proliferation, and survival of Tregs; inhibition of p38 results in 
reduced TNF-mediated induction of Tregs. This study does not distinguish between 




only explain an upregulation for a proportion of the CD4+ population. Hypothetically, 
if p38 were evidenced to be upregulated in Tregs, and functioning to support Treg 
function and survival, it may suggest p38 is unlikely implicated in non-responsiveness 
to Humira in this patient. This is hypothesised knowing that anti-TNF-induced, MAPK-
dependent Tregs contribute to therapeutic efficacy in responders.  
Tregs will not account for the whole CD4+ population, therefore patient 3 is likely 
showing upregulated p38 in effector T cells as well. There is significant ERK, p38 and 
NFĸBp65 pathway redundancy where TNF is not the only mediator (29, 48). Other 
inflammatory cytokines including, but not limited to, IL-6, IL-17 and IL-23, have been 
shown to activate these pathways (1, 42). Given upregulated P-p38 was in response 
to PMA/ionomycin stimulation and not TNF stimulation, this may suggest other pro-
inflammatory cytokines are mediating p38 pathways in effector T cells and likely 
contributing to inflammation. This would conclude anti-TNF may not be effective if TNF 
is not the major contributor to p38 activation in effector, pro-inflammatory T cells. 
Patient 3 was also presumed to be in an active disease state at the time of sample 
collection (Table 2.1). Provided p38 has been implicated in inflammatory responses in 
effector T cells of IBD patients (47, 48), upregulated p38 in pro-inflammatory T cells of 
this patient is not unlikely. 
Interestingly, a study showed an upregulation of P-p38 in T cells in both anti-TNF 
responders and non-responders; however, only responders showed p38-mediated 
activation of transcription factors ATF-1 and Hsp27 (45). Despite upregulated active 
p38, non-responders failed to exhibit phosphorylation of these transcription factors 
(45). The study did not conclude what the functional consequence of ATF-1 and Hsp27 




heterogeneity and suggests some therapeutic benefit seen with specific p38 inhibition 
(47, 78) may be independent of the effects of p38 inhibition/modulation mediated by 
anti-TNF.  
Given p38 has different functions in Tregs and effector T cells, in the context of IBD, 
perhaps anti-TNF works to inhibit P-p38-mediated inflammation in effector T cells, 
whilst simultaneously stabilising P-p38 in Tregs, both of which would contribute to 
therapeutic efficacy in responders. 
Irrespective of hypotheses, these data do not provide insight into an anti-TNF non-
response mechanism or contributor, in patient 3. This is because of the potential 
confounding effect other immunosuppressant treatments may have on the patient’s 
TNF signalling profile. Furthermore, this study did not investigate the functional activity 
of p38 in this patient or other patients, failing to provide a mechanistic link between 
protein expression and anti-TNF response. These data do, however, encourage 
further investigation into how p38 is acting functionally with respect to its downstream 
target proteins and upstream regulators in individuals with IBD.  
Specifically, this study merits further investigation into what CD4+ T cell subsets are 
expressing upregulated p38 and how these proteins function in these subsets. This 
would provide insight into either negating or implicating this pathway in non-
responsiveness in this patient, but also provide further understanding into the 
mechanisms of anti-TNF. Supporting this idea, is a recent study by Papoustopoulou 
and authors (2019) (79) which stratified IBD patients into smaller subgroups based on 
macrophage NFĸBp65 activity. This study supports the idea that proteins may not 




concept of signalling heterogeneity. Interestingly, their findings showed a link between 
high NFĸBp65 activity and smoking, which was not evidenced in smokers and non-
smokers in the healthy group. Smoking is an environmental risk factor for IBD and is 
thus relevant to pathogenesis. This study is an example of using signalling dynamics 
to account for individual heterogeneity and contributors to pathological mechanism 
(79).  
4.3 Technical considerations and limitations 
Analysis of p38, NFĸBp65 and ERK using phosphoflow cytometry is not well 
represented in the literature. Optimisation of phosphoflow cytometry therefore requires 
highly specific adjustments, in addition to general recommendations made by the 
literature. Optimisation of TNF stimulation evidenced that resting cells prior to 
stimulation did not increase the MFI fold change of phosphorylated protein expression 
(Figure 3.8), contrary to what is suggested by literature. However, theory suggests 
resting cells prior to stimulation reduces basal phosphorylation induced by mechanical 
and temperature stress (55), consequently allowing a larger stimulation-induced 
change in MFI. Schulz and authors (2007) (55) discuss considerations when resting 
immune cells prior to in vitro stimulation for phosphoflow cytometry analysis. Resting 
cells for too long may be detrimental to cell viability and functionality (55), however 
some studies employ or suggest overnight rest periods (63). More commonly reported, 
though, are rest times between 1-4 hours as tested in this study. A recent phosphoflow 
protocol published by Rip and authors (2020) (80) rested B cells for 1-3 hours prior to 
stimulation; however, this was not compared to a no-resting state prior to stimulation. 
The data presented in this study may not have shown an effect of resting cells on MFI 




therefore, variability could confound significant changes in MFI fold change following 
1 or 4 hours rest. Given little response to in vitro TNF stimulation, compared to pan-
stimulation in this study, re-addressing factors of TNF stimulation optimisation would 
be considered in the future.  
There were two major limitations of the current protocol which were not addressed but 
should be in the future. The time between stimulation and fixation may have resulted 
in ‘missing’ transient, shorter phosphorylation events. Stimulation of TNF pathways 
causes a change in phosphorylation levels. Fixation is the process that allows the 
capture of transient biological events (55). The time between inducing phosphorylation 
(stimulation) and fixation was anywhere between 1 hour – 2 hours. This time gap was 
due to live/dead and surface staining and dependent on how many samples were 
being analysed at once. Phosphorylation kinetics may suggest that the time between 
stimulation and fixation may result in dephosphorylation occurring before fixation (81). 
Unfortunately, this may mean any short-lived differences in phosphorylation was not 
identified in this study; furthermore, it may explain why there were some fold changes 
less than 1 (Figure 3.10 and Figure 3.12). 
It was not verified whether the BD phosphoflow buffer used in this protocol permeated 
the nuclear membrane. Given NFĸBp65 is a transcription factor and the p65 subunit 
can translocate to the nucleus post-phosphorylation, results shown here may not 
include translocated P-p65. This may lead to a potential systematic under-
representation of phosphorylated NFĸB-p65 expression.  
Phosphorylated protein expression showed small increases from the unstimulated 




was high prior to stimulation due to in vitro stress, the resulting phosphorylation 
induced by stimulation, would be much smaller. This is a potential explanation for small 
fold changes in MFI, however this may just be representative of the population studied.  
4.4 Strengths and limitations  
This study has used a specifically tailored methodology to identify signalling pathways 
related to TNF. The strengths of this technique are that unlike western blots and other 
methods used to detect phosphorylated protein expression, phosphoflow can quantify 
multiple proteins at once (55). Furthermore, phosphoflow enables cell phenotyping 
simultaneously, which allows identification of phosphorylated proteins in specific cell 
populations. 
Patient samples 
Clinical immunology needs to prioritise the use of patient samples and individual 
analysis for immunologically heterogeneous diseases, such as IBD, given disparate 
outcomes of biological and immune-based therapies (50). While patient blood samples 
are the experimental ideal for the study of most diseases, multiple limitations do arise 
from this. Patient sample availability was varied, meaning samples were analysed in 
independent experiments. This can result in increased variability between 
experimental technique and analysis inconsistencies, meaning data may be less 
comparable between experiments.  
Patient history and clinical notes are incredibly important to understand how results 
may be affected by confounding factors such as drug regimens. In this study some 
patients had incomplete medication history meaning it was unknown if the patient was 




analysis, I was unable to ensure I was analysing anti-TNF patients. This meant I had 
only one patient on anti-TNF and was unable to compare a non-responder to a 
responder, limiting insight into the differences between these two groups and what 
may be contributing to non-response at a molecular level.  
Whilst this study took into consideration the possible effects of current treatments on 
the TNF signalling profiles of individual IBD patients, this was all hypothetical. There 
was no knowledge of pharmacotherapeutic regimens and thus, it must be accounted 
for, that these drugs may act differently within people due to the immune heterogeneity 
this study aims to address. Ideally, treatment naïve patients (ie. newly diagnosed 
patients) would be optimal for addressing baseline expression of proteins prior to anti-
TNF treatment, but this is unrealistic due to the nature of disease and disease 
treatment.  
Sample size 
Although some heterogeneity is seen, because the sample size is limited, is it is 
difficult to know if the two patients of interest are representing protein expression that 
is substantially different. This is particularly for the analysis of phosphorylated 
NFĸBp65 expression in the IBD group which had two patients. 
4.5 Implications  
The experimental approach taken in this study to consider individual signalling profiles 
aims to address conflicting literature about the roles of signalling proteins, p38, ERK 
and NFĸBp65 in the context of a heterogeneous disease. These data have shown 
preliminary evidence that IBD patients do show signalling heterogeneity. Whilst one 




relationship between signalling expression and therapy non-response, nor a predictor 
of response. However, the long-term, bigger picture of this study is to uncover 
heterogeneity such as this, which could potentially explain a mechanism of non-
response or a predictor of response.  
Finding predictors of response or mechanisms of non-response would enable 
clinicians to treat patients correctly from the start of an IBD diagnosis. This would in 
turn improve quality of life for longer by maintaining remission from the start of 
diagnosis and reduce burden on the public health care system.  
4.6 Future directions 
Immediately I would aim to adjust my protocol to address technical limitations in this 
study. This would involve attempting to fix cells closer to after stimulation as described 
(55). Some phosphoflow methods discuss issues with reduced CD protein expression 
when fixing prior to surface staining, which requires future investigation. Additionally, 
optimising TNF stimulation further may involve a time-dose response curve to more 
accurately determine the optimal concentration and stimulation time for induction of 
ERK, p38 or NFĸBp65 phosphorylation.  
To investigate the potential p38 upregulation in patient 3 or address its heterogeneity 
at the individual level, future studies would need to further phenotype the CD3+ CD4+ 
T cell population to distinguish between effector T cells and regulatory T cells. To do 
this, population phenotypes would be based on cytokine production, transcription 
factors and surface proteins. Cytokine production and transcriptional analysis would 




would also then address whether proteins are functioning differently, even when they 
may be expressed in an activated state at a similar level, between individuals.  
Upon the findings of a robust link between heterogeneity of a signalling pathway and 
anti-TNF non-response, an in vitro anti-TNF challenge would see the TNF signalling 
profiles of anti-TNF treated and anti-TNF naïve immune cell subsets.   
Considering the interplay between immune response and the IEB, repeating these 
experiments on intestinal biopsy samples may provide more insight into mechanisms 
of non-response. The IEB is important in IBD pathology and TNF is known to play a 
crucial role in maintaining cell turn over (8), therefore it would be worth considering 
heterogeneity of TNF signalling in intestinal epithelial cells.  
5. Conclusion  
Crohn’s disease and Ulcerative colitis are highly prevalent in New Zealand. IBD is a 
highly heterogeneous disease due to genetic, environmental, microbiome and immune 
system implications, meaning IBD likely exists as a mechanistic spectrum. TNF 
contributes to the pathological intestinal, mucosal immune response, characterising 
IBD pathology; however inhibiting TNF via anti-TNFs has disparate therapeutic 
response. TNF signalling is highly dynamic, exhibiting functional heterogeneity 
between cell types and dependency on cellular context. This means patients may 
require different treatments for maintained remission. Given conflicting outcomes of 
inhibiting downstream TNF-signalling proteins and evidence of their diverse functions 
in other contexts, the aim of this study was to investigate this at an individual level, 
within an IBD cohort. To do this, a phosphoflow protocol was optimised to visualise 




stimulation or PMA/ionomycin stimulation. Data presented in this study failed to show 
significant differences between a healthy cohort and IBD cohort; however this was 
potentially due to immunosuppressive medications confounding any differences, or a 
low sample size, where a larger sample size may negate such confounders. When 
comparing individual IBD patients, two patients were considered patients of interest 
due to substantially different levels of phosphorylated protein expression in response 
to PMA/ionomycin stimulation. These data exhibited heterogeneity between IBD 
individuals, supporting the hypothesis that signalling proteins may act diversely 
between IBD individuals. Of particular interest, was heterogeneity observed in an anti-
TNF non-responder which prompts further investigation. Following future directions, 
this study could provide insight into potential molecular mechanisms contributing to, 
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7. Appendix  
Figure 7.1 FMOs were used to guide gating of CD3+, CD4+ and  CD8+ T cell populations. 
A healthy PBMC sample was defrosted and stained with fluorescently labelled antibodies and 
fixed with PFA. FMOs were stained for all fluorescent antibodies except 1, as indicated, and 
fixed with PFA. Populations here were previously gated on live PBMCs via FlowJo Software.  
